// App-Quantinova.ai

PB2477 : VTE Treatment in Routine Clinical Practice: A Pre-specified Combined Evaluation of XALIA and XALIA-LEA with Additional Analyses of Special Patient Populations

Researchers

Presenter

  • S. Haas

Principal Investigators

  • L.G. Mantovani

  • R. Kreutz

  • D. Monje

  • J. Schneider

  • E. Zell

  • M. Tamm

  • M. Gebel

  • J.-P. Bugge

  • W. Ageno

  • A.G.G. Turpie

Medical Centers

  • Technical Univ of Munich, Munich, Germany

  • IRCCS MultiMedica, Sesto S. Giovanni (MI), Italy

  • University of Milan Bicocca, CESP-Center for Public Health Research, Monza, Italy

  • Charite-Universitatsmedizin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany

  • Bayer, Berlin, Germany

  • Stat-Epi Associates Inc., Ponte Vedra Beach, United States

  • Bayer Pharma AG, Berlin, Germany

  • University of Insubria, Department of Medicine and Surgery, Varese, Italy

  • McMaster University, Internal Medicine, Hamilton, Canada

Locations

  • Germany

  • Italy

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved